COMP <GO>
VCYT vs UNH // NET PROFIT MARGIN
Veracyte Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: VCYT 7
— UNH 8
▲ NET PROFIT MARGIN LEADER: VCYT
LAST: $50.01 (-4.14%) • MKT CAP: $4.19B
net-margins
12.80%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
net-margins
3.14%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCYT VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCYT | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.10% | 88.57% | -18.47 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 11.47% | -6.87 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 58.7x | 16.4x | +42.25 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 3.02% | 6.48% | -3.46 | UNH | /fcf-yield <GO> |
| Operating Margin | 11.20% | 4.82% | +6.38 | VCYT | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 12.80% | 3.14% | +9.66 | VCYT | /net-margins <GO> |
| Revenue Growth (YoY) | 16.00% | 6.46% | +9.54 | VCYT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.12 | +22.88 | VCYT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | VCYT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.74% | +0.46 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.9 | 56.0 | +4.87 | VCYT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.33 | +0.75 | VCYT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 53.1x | 17.1x | +36.01 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.19B | $364.66B | -$360.47B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCYT REV | UNH REV | VCYT GROSS % | UNH GROSS % | VCYT FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $517.1M | $447.57B | 70.1% | 88.7% | $126.6M | $16.07B |
| FY 2024 | $445.8M | $400.28B | 66.9% | 88.3% | $63.8M | $20.70B |
| FY 2023 | $361.1M | $371.62B | 44.0% | 89.6% | $28.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCYT // BETA 1.08
UNH // BETA 0.33